What is it? · Laboratory-made kratom-related derivative

What is MGM-16?

MGM-16 is a shorthand name for the compound DEA identifies as 9-fluoro-dihydro-7-hydroxymitragynine, also numbered 10-fluoro-dihydro-7-hydroxymitragynine under another convention. It is a separate laboratory-made kratom-related compound. The name does not describe natural leaf, a strain, or conventional mitragynine extract.

MGM-169-Fluoro-dihydro-7-hydroxymitragynine; 10-fluoro-dihydro-7-hydroxymitragynine (numbering convention)

Category

Laboratory-made kratom-related derivative

Also called

9-Fluoro-dihydro-7-hydroxymitragynine; 10-fluoro-dihydro-7-hydroxymitragynine (numbering convention)

Key distinction

Ingredient identity and manufacturing process matter more than a trade name.

MGM-16: advised against.

DEA identifies MGM-16 among the potent opioid compounds covered by its temporary order. We advise against products containing it. A similar name, tablet size or marketing category does not establish a reliable equivalence to another alkaloid or leaf product.

From leaf to ingredient

Where does it come from?

The fluoro part of its chemical name identifies a fluorine-related structural modification. This chemical modification distinguishes the compound from simply extracting mitragynine from the leaf.

Read the label

What makes it different?

MGM-16 is not MGM-15, and the 9 in its chemical name does not make it MIT-9 or 9-ODM. Similar-looking alkaloid names can identify different molecules; check the complete chemical identity.

What is its legal status?

MGM-16 and covered forms were placed in federal Schedule I effective August 26, 2026. The October 14 companion notice preserves the existing approach pending a later action. State and local restrictions apply separately.

Check federal, state and local law

Read the originals

Sources & further reading

Legal sources reviewed: November 17, 2026.

Responsible-use guidance covers interactions, dependence and other precautions.